CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 43 enrolled
Drug / intervention
No Interventionother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02181530
NCT02181530N/ACompleted

Retrospective Data Collection Study in Patients With Macular Oedema Receiving OZURDEX®

Allergan·observational·Posted Jul 4, 2014·Updated May 25, 2015

In Brief

An observational study evaluating No Intervention for Macular Edema and Retinal Vein Occlusion. Completed, enrolled 43 participants across 1 site.

Detailed Summary

This study will use retrospective data to evaluate the safety and efficacy of OZURDEX® (dexamethasone intravitreal implant 0.7 mg) in the treatment of macular oedema due to retinal vein occlusion (RVO) in clinical practice. No intervention will be administered as part of this study.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesPoland
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 4, 2014
Enrollment StartJul 1, 2014
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 12.0 years ago

Interventions

No Interventionother

No treatment (intervention) is being administered as part of this study.